3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
145
Lymphoma
104
Lymphoma, Large B-Cell, Diffuse
76
Sarcoma
62
Hodgkin Disease
46
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Burkitt Lymphoma
36
Triple Negative Breast Neoplasms
31
Lymphoma, Non-Hodgkin
29
Lymphoma, Mantle-Cell
27
Leukemia
25
Neoplasms
22
Lymphoma, Follicular
22
Neoplasm Metastasis
21
Multiple Myeloma
21
Neuroblastoma
20
Carcinoma, Hepatocellular
18
Ovarian Neoplasms
16
Lymphoma, B-Cell
16
Liver Neoplasms
14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
13
Urinary Bladder Neoplasms
12
Osteosarcoma
12
Lymphoma, T-Cell, Peripheral
11
Lymphoma, Large-Cell, Anaplastic
11
Inflammatory Breast Neoplasms
11
Breast Neoplasms, Male
11
Prostatic Neoplasms
10
Dendritic Cell Sarcoma, Interdigitating
10
Lymphoma, Large-Cell, Immunoblastic
9
Interventions
Paclitaxel
2
Nivolumab
2
Bevacizumab
2
liposomal doxorubicin
1
dostarlimab
1
Sunitinib
1
Radiotherapy
1
Ipilimumab
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Celecoxib
1
Carboplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma, Clear Cell
×
Doxorubicin
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled